Enhancing Virus Clearance Process Capability Using a Biodegradable Detergent
To ensure the safety of biopharmaceuticals derived from mammalian cell culture, it is critical biomanufacturing processes can clear or inactivate potential viral contaminants.
Though rare, virus contaminations are a real threat to patients. The consequences of such events are dire for patients of course, and manufacturers could see catastrophic losses as well. Purification process steps are the final shield to prevent viral contamination, and a viral inactivation solution can be an effective method to improve clearance and alleviate viral burden downstream.
Read about new study data, challenges and opportunities of viral inactivation giving the proof of benefits of J.T.Baker® Viral Inactivation Solution.
Senior Manager – Bioprocess Application, Avantor
Tuhidul Islam is a Sr. Manager – Bioprocess Application at Avantor. He is focused on applications of new products and processes to overcome challenges in biologics manufacturing for different drug modalities. Tuhidul holds a PhD in Biochemical Engineering, with a particular focus on protein purification method development. He has 14+ years of experience in process development and cGMP manufacturing science for monoclonal antibodies, fusion proteins, Adeno-associated virus and Lentivirus.
Dr. Jungmin Oh
Manager, New Product Development
In her current role, Jungmin leads product and process development projects with multiple biopharmaceutical industry partners, including customized product development for cell and gene therapy customers. She holds a MS and Ph.D. in chemical engineering, specializing in the optimization of a continuous chromatography system.
Dr. Nandu Deorkar
Senior Vice President, Research & Development – Biopharma Production, Avantor
Nandu Deorkar is Senior Vice President, Biopharma Production Research & Development for Avantor. He is responsible for innovation strategy and planning, and execution of new products and technology development. During his more than 25-year career in research & development, Dr. Deorkar has been leading teams working on various aspects of upstream and downstream bioprocessing, single use systems, chemical/polymer R&D, drug development, formulation, drug delivery technologies, process development, and technology transfer. He has published more than 30 articles and holds more than 20 patents. Dr. Deorkar received Ph.D. from Indian Institute of Technology, Mumbai, India and MBA in Marketing from Fairleigh Dickinson University, Madison, NJ, USA.